Molecular targets of atypical antipsychotics: From mechanism of action to clinical differences

Stefano Aringhieri; M. Carli; Shivakumar Kolachalam; Valeria Verdesca; E. Cini; M. Rossi; P. McCormick; G. Corsini; R. Maggio; M. Scarselli

DOI:10.1016/j.pharmthera.2018.06.012

Corpus ID: 49602956

Molecular targets of atypical antipsychotics: From mechanism of action to clinical differences

@article{Aringhieri2018MolecularTO,
  title={Molecular targets of atypical antipsychotics: From mechanism of action to clinical differences},
  author={Stefano Aringhieri and M. Carli and Shivakumar Kolachalam and Valeria Verdesca and E. Cini and M. Rossi and P. McCormick and G. Corsini and R. Maggio and M. Scarselli},
  journal={Pharmacology & Therapeutics},
  year={2018},
  volume={192},
  pages={20–41}
}

Stefano Aringhieri, M. Carli, +7 authors M. Scarselli

Published 2018

Medicine, Biology

Pharmacology & Therapeutics

ABSTRACT The introduction of atypical antipsychotics (AAPs) since the discovery of its prototypical drug clozapine has been a revolutionary pharmacological step for treating psychotic patients as these allow a significant recovery not only in terms of hospitalization and reduction in symptoms severity, but also in terms of safety, socialization and better rehabilitation in the society. Regarding the mechanism of action, AAPs are weak D2 receptor antagonists and they act beyond D2 antagonism… CONTINUE READING

View on Wolters Kluwer